Guardant Health, Inc.

As of June 30, 2026, Guardant Health, Inc. carries a market capitalization of 17.52B, placing it among publicly traded companies globally. Its enterprise value stands at 18.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Guardant Health, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Guardant Health, Inc. has 133.61M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 16.39, and the price-to-book ratio stands at -89.82.

These figures are as of June 30, 2026. The EV/Sales ratio of 17.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 18.09B versus a market cap of 17.52B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Guardant Health, Inc. maintains a current ratio of 4.03, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -761.45, indicating conservative leverage, while an interest coverage ratio of -89.66 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -27.95, reflecting losses generated across the asset base. The company generates approximately 434,247.53 in revenue per employee across its workforce of 2,384.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.37 indicates how many times Guardant Health, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Guardant Health, Inc. recorded an income tax benefit of -905,060.20 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -397.80M and -396.89M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Guardant Health, Inc.'s stock has gained approximately 146.40% over the past 52 weeks. The 50-day moving average sits at 146.12, while the 200-day moving average is 111.64.

Over the twelve months ended June 30, 2026, Guardant Health, Inc. generated 1.04B in revenue and converted that into -396.89M in net income, yielding earnings per share of -3.07. EBITDA reached -377.96M, while operating income came in at -411.62M.

As of June 30, 2026, Guardant Health, Inc. holds 922.10M in cash and equivalents against 1.49B in total debt, resulting in a net debt position of 393.42M. Total book value stands at -195.08M, with working capital of 897.78M providing operational flexibility.

Guardant Health, Inc. produced -162.09M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -48.61M in capital expenditures, free cash flow totaled -210.71M - equivalent to -1.63 per share.

Over the twelve months ended June 30, 2026, Guardant Health, Inc. posted a gross margin of 65.01, reflecting its pricing power and cost economics. The operating margin of -39.75 and net profit margin of -38.33 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.24: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.69, meaning Guardant Health, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Guardant Health, Inc. has an Altman Z-Score of 3.61, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.